摘要
目的探讨贝利尤单抗联合吗替麦考酚酯治疗系统性红斑狼疮(SLE)的临床疗效。方法选取海南医学院第二附属医院和天津市儿童医院2021年2月至2022年1月收治的SLE患者52例,按随机数字表法分为观察组和对照组,各26例。两组患者均在常规治疗基础上口服吗替麦考酚酯分散片,观察组患者加予注射用贝利尤单抗静脉滴注。两组均连续治疗3个月。结果观察组总有效率为96.15%,明显高于对照组的73.08%(P<0.05)。治疗后,观察组患者系统性红斑狼疮疾病活动度量表、系统性狼疮活动测量表、英国狼疮评价量表评分均明显低于对照组(P<0.05);观察组患者补体C3、补体C4水平均明显高于对照组,免疫球蛋白G水平明显低于对照组(P<0.05);观察组患者白细胞介素2、辅助性T细胞17、甘露糖结合凝集素水平均明显低于对照组(P<0.05)。观察组与对照组不良反应发生率相当(15.38%比11.54%,P>0.05)。结论贝利尤单抗联合吗替麦考酚酯治疗SLE效果良好,可改善患者的症状评分、免疫学指标和炎性指标。
Objective To investigate the clinical efficacy of belimumab combined with mycophenolate mofetil in the treatment of systemic lupus erythematosus(SLE).Methods A total of 52 patients with SLE admitted to the Second Affiliated Hospital of Hainan Medical College and Tianjin Children's Hospital from February 2021 to January 2022 were selected and divided into the observation group and the control group by the random number table method,with 26 cases in each group.On the basis of routine treatment,the patients in the two groups were orally given Mycophenolate Mofetil Dispersible Tablets,and the patients in the observation group were added intravenous drip of Belizumab for Injection.Both groups were treated continuously for three months.Results The total effective rate in the observation group was 96.15%,which was significantly higher than 73.08%in the control group(P<0.05).After treatment,the scores of the Systemic Lupus Erythematosus Disease Activity Index(SLEDAI),Systemic Lupus Activity Measurement(SLAM)and British Isles Lupus Assessment Group index(BILAG)in the observation group were significantly lower than those in the control group(P<0.05).The levels of complement C3 and C4 in the observation group were significantly higher than those in the control group,while the level of immunoglobulin G(IgG)in the observation group was significantly lower than that in the control group(P<0.05).The levels of interleukin-2(IL-2),helper T-cell 17(Th17)and mannose-binding lectin(MBL)in the observation group were significantly lower than those in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was similar to that in the control group(15.38%vs.11.54%,P>0.05).Conclusion Belizumab combined with mycophenolate mofetil is effective in the treatment of SLE,and can improve the symptom score,immunological index and inflammatory indexes of patients.
作者
林千祺
许夏雨
邢诒喜
黄美琼
姚奇岑
陈艺玲
梁金
周秋梅
陈维飞
LIN Qianqi;XU Xiayu;XING Yixi;HUANG Meiqiong;YAO Qicen;CHEN Yiling;LIANG Jin;ZHOU Qiumei;CHEN Weifei(Department of Rheumatology and Immunology,The Second Affiliated Hospital of Hainan Medical College,Haikou,Hainan,China 570311;Department of Nephrology,Tianjin Children′s Hospital,Tianjin,China 300134)
出处
《中国药业》
CAS
2023年第2期86-89,共4页
China Pharmaceuticals
基金
海南省医药卫生科研项目[2101320244A2001]。
关键词
系统性红斑狼疮
贝利尤单抗
吗替麦考酚酯
临床疗效
炎性指标
免疫功能
systemic lupus erythematosus
belizumab
mycophenolate mofetil
clinical efficacy
inflammatory index
immune function
